Authors

Saro Arakelians, PharmD

Latest:

Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Jordan Axelrad, MD, MPH

Latest:

Common Questions From Patients About Adalimumab Biosimilars

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Dinakaran Balasubramanian

Dinakaran is an accomplished commercial professional with rich experience of over 12 years in the pharmaceutical industry. He has an extensive understanding of the US commercial landscape and its key economic drivers, specifically in generic injectables and biosimilars. He is currently serving as the Head of Commercial Strategy & Insights for Biologics in North America for Dr Reddys Laboratories. His role extends to providing valuable insights into pricing considerations, competitive intelligence, and market dynamics, crucial for driving product adoption and profitability objectives. During his long tenure, he has handled multiple roles across Sales, strategy, pricing, and product management.

Latest:

The Underlying Economics of Unbranded Biologics

Unbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.

Kostas Botsoglou, MD

Latest:

Common Questions From Patients About Adalimumab Biosimilars

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Travis Brewer serves as the vice president of payer and public health strategy at Texas Oncology.

Latest:

Enhancing Biosimilar Adoption in Value-Based Oncology Care

Travis Brewer, vice president of payer and public health strategy at Texas Oncology, discusses the role of biosimilars in making cancer care more affordable and accessible, as well as the need for greater payer trust in oncologists’ treatment decisions.

Jamie T. Brogan, MSN, APRN, FNP-BC

Latest:

Common Questions From Patients About Adalimumab Biosimilars

Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.

Josh Canavan, PharmD

head of pharmacy at RazorMetrics

Latest:

How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?

James D. Chambers, PhD, MPharm, MSc

James D. Chambers, PhD, MPharm, MSc, is an associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies. Chambers leads the Tufts Medical Center Specialty Drug Evidence and Coverage Database and the Medicare National Coverage Decisions Database, making him a key expert in analyzing drug policy, reimbursement trends, and health care economics. Chambers is also partnering with Organon to share his insights as a health economist around the complex landscape of biosimilars.

Latest:

The Banking of Biosimilars: Insights From a Leading Health Economist

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.

Anna Chen, PharmD, MS

Latest:

Budget Impact Analysis of Biosimilar Natalizumab in the US

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.

Advertisement

Advertisement